menu
    • menu

    Company profile for Tesaro

    Metrochem has been delivering customized volume & quality products to customers across the world, taking utmost care of their needs.

    Virtual Booth

    Contact Supplier

    With Virupaksha, you get a quality product with on-time delivery.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2025-11-24

    Virtual Booth

    Contact Supplier

    Munit offers scalable GMP micronization and particle size engineering to enhance drug solubility, bioavailability, and performance.

    Virtual Booth

    Contact Supplier

    ChemExpress delivers end-to-end CRO & CDMO solutions for small molecules, biologics & new modalities with ICH-grade quality.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    TESARO is a biopharmaceutical company devoted to providing transformative therapies to people bravely facing cancer. We see new possibilities to responsibly develop and commercialize innovative treatments where others may not. Relationships are vital to the success of our business, and we are committed to being a trusted partner to the cancer community.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    TesaroUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    TESARO 1000 Winter Street Waltham, MA 02451
    Telephone
    Telephone
    +1 339 970 0900
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.gsk.com/en-gb/about-us/tesaro-is-now-part-of-gsk/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/tesaro
    youtube
    YouTube
    Twitter
    Twitter
    https://x.com/TESAROBIO?ref_src=twsrc%5Egoogle%7Ctwcamp%5Eserp%7Ctwgr%5Eauthor

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Default Event

    DDL Conference

    Not Confirmed

    envelop Contact Supplier

    DDL Conference

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    UK court orders GSK to pay AstraZeneca royalties on total sales of Zejula
    UK court orders GSK to pay AstraZeneca royalties on total sales of Zejula

    06 Apr 2023

    // REUTERS

    https://www.reuters.com/business/healthcare-pharmaceuticals/uk-court-orders-gsk-pay-astrazeneca-royalties-total-sales-zejula-2023-04-05/

    REUTERS
    06 Apr 2023
    Share Share
    Merck's Vaxneuvance lead departs for Affinivax—Chutes & Ladders
    Merck's Vaxneuvance lead departs for Affinivax—Chutes & Ladders

    13 Aug 2021

    // Kyle LaHucik FIERCEBIOTECH

    https://www.fiercebiotech.com/biotech/chutes-ladders-merck-s-vaxneuvance-lead-exits-to-make-rival-vaccine-at-affinivax

    Kyle LaHucik FIERCEBIOTECH
    13 Aug 2021
    Share Share
    With Tesaro staff and expertise in the mix
    With Tesaro staff and expertise in the mix

    14 Jan 2020

    // Eric Sagonowsky FIERCE PHARMA

    https://www.fiercepharma.com/pharma/jpm-tesaro-staff-and-expertise-mix-gsk-gears-up-for-3-oncology-launches-2020

    Eric Sagonowsky FIERCE PHARMA
    14 Jan 2020
    Share Share
    GSK, AZ-Merck PARP data heap pressure on Clovis: analysts
    GSK, AZ-Merck PARP data heap pressure on Clovis: analysts

    02 Oct 2019

    // Angus Liu FIERCE PHARMA

    https://www.fiercepharma.com/marketing/as-gsk-and-az-merck-show-off-dazzling-parp-data-where-does-leave-clovis-rubraca

    Angus Liu FIERCE PHARMA
    02 Oct 2019
    Share Share
    AstraZeneca rounds out ESMO for expanded biomarker in prostate cancer
    AstraZeneca rounds out ESMO for expanded biomarker in prostate cancer

    30 Sep 2019

    // Amber Tong ENDPTS

    https://endpts.com/beyond-brca-astrazeneca-rounds-out-esmo-with-a-case-for-expanded-biomarker-in-prostate-cancer/

    Amber Tong ENDPTS
    30 Sep 2019
    Share Share
    AbbVie's PARP inhibitor veliparib finally gets a win, but can it compete?
    AbbVie's PARP inhibitor veliparib finally gets a win, but can it compete?

    29 Sep 2019

    // Ben Adams FIERCE BIOTECH

    https://www.fiercebiotech.com/biotech/esmo-abbvie-s-parp-veliparib-finally-gets-a-win-but-can-it-compete

    Ben Adams FIERCE BIOTECH
    29 Sep 2019
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search